Innovations in Immunity

inSIGHT™ T Cell diagnostic delivers a deeper understanding of patients' response to viral antigens

  • Assess current immune response for viral target

  • Confirm if virus specific CD4 and CD8 T Cells are present

  • Evaluate treatment decisions

Learn more about Eurofins Viracor inSIGHT™ for examining T cell response:

CMV T Cell Immunity Test EBV T Cell Immunity Test

holding childs hand with IV
EBV inSIGHT™ T Cell Immunity test is now available to order.

The test measures the strength of T cell responses to EBV specific antigens, lytic antigen BZLF1 and latent antigen EBNA3. It evaluates and reports polyfunctional and Interferon-gamma activity of CD4 and CD8 T cell responses independently.

In the transplant setting, post-transplant lymphoproliferative disorders (PTLD) can arise as a consequence of immunosuppression and the loss of T cells that typically control reactivation of EBV. Rapidly rising EBV viral loads can indicate patients at risk for PTLD, a critical cause of morbidity and mortality in, SOT and HSCT patients

inSIGHT CMV EBV logos

It's your job to keep patients safe; our job is to help you do it.

The Advantages of inSIGHT™

With inSIGHT™, you're now armed with the data to help answer critical questions: Is the patient's body producing a T Cell response? Is that response strong enough to make treatment adjustments? Are they ready to discontinue antiviral medication?

For Clinical Staff

  • Reports CD4 and CD8 responses separately
  • Provides numerical values for various reportables
  • Ability for result consultation with scientific liaisons

For Lab Staff

  • Does not require additional staff or training
  • Live cell ambient shippers available
  • Simple blood draw, no extra processing to isolate PBMC
Menu

CASE STUDY: Review a bi-lateral lung transplant patient case study to see how they utilized inSIGHT testing to evaluate prophylaxis.

CMV Immunity Testing in a Lung Transplant Recipient

CMV inSIGHT T Cell Immunity Testing Case Study

Addressing CMV in Solid Organ Transplant Patients with CMV inSIGHTTM T Cell Immunity

Justin Rosenheck, DO
Assistant Professor of Internal Medicine at Ohio State University		 Dr Kapil Kumar Saharia, MD, MPH
Chief, Solid Organ Transplant Infectious Disease at University of Maryland School of Medicine		 Dr. Abhay Dhand, MD, FIDSA
Director of Transplant Infectious Disease at Westchester Medical Center

These knowledgeable physicians share how they manage their solid organ transplant patients at risk for CMV by utilizing CMV inSIGHT™ T Cell immunity. These unique case studies will cover situations like neutropenia, low-level CMV, the importance of CD4 T Cells and more. Learn when they use CMV inSIGHT T Cell Immunity testing to evaluate CMV-specific cell mediated immunity, what they do with the information from the lab report, and the outcomes of their patients. Including a recording of the Live Q&A at the end of the original presentation.

In this webinar you will learn how the physicians utilize CMV inSIGHT in the following solid organ transplant cases:

  • Neutropenic patient
  • Low-level CMV DNAemia
  • Importance of CD4 T Cell Response
  • In instances of CMV Resistance
  • When belatacept is used for immunosuppression

inSIGHT Presentations Form

IDWeek 2021 - "Gain inSIGHT into an Immunocompromised Patient's T Cell Immune Response featuring: CMV and SARS-CoV-2"

Dr. Nirav Raval
Medical Director of Thoracic Transplant, Transplant Cardiologist
Advent Health		 Dr. Fareed Khawaja
Assistant Professor, Department of Infectious diseases, Infection Control and Employee Health
University of Texas MD Anderson Cancer Center		 Dr. Steve Kleiboeker
Vice President of Research and Development
Eurofins US Clinical Diagnostics

Join Dr.'s Raval, Khawaja and Kleiboeker to learn more about virus-specific T cell immunity for CMV and SARS-CoV-2. Dr. Raval, a board-certified Cardiologist, will share his experience utilizing the CMV T Cell Immunity panel in heart transplant patients. Dr. Khawaja, an Infectious Disease physician, will present his experience with CMV cellular immunity in hematopoietic cell transplant recipients with low level viremia. Finally, Dr. Kleiboeker will describe the new SARS-CoV-2 inSIGHT T Cell Immunity test as well as discuss future T Cell Immunity testing innovations to come.

inSIGHT Presentations Form

The 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR - "Innovative Diagnostics to Help Manage HSCT Complications Post-Transplant"

Dr. Roy Chemaly
MD, MPH, FIDSA, FACP
University of Texas MD Anderson Cancer Center

Dr. Fareed Khawaja
MD
University of Texas MD Anderson Cancer Center

 Dr. Steve Kleiboeker
Vice President of Research and Development
Eurofins US Clinical Diagnostics

Learn about an ongoing study which Dr. Chemaly and his team at MD Anderson have utilized CMV inSIGHT™ T Cell Immunity testing to:

  • Identify cellular therapy recipients (both on and off letermovir for prophylaxis) who are high risk for clinically significant CMV infection.
  • Assess the benefit of early treatment of low level CMV viremia who are not on letermovir prophylaxis and high risk for clinically significant CMV infection
  • Determine utility of the CMV inSIGHT™ T Cell Immunity test in the management of low level CMV viremia in high and low risk patient populations on letermovir.

 

inSIGHT Presentations Form

The ability to monitor the presence or absence of virus specific, highly functional T cells will be an important tool, along with monitoring viral load, in managing patients post-transplant as their immune system recovers.
EBV T Cell Immunity Testing Abstract Poster Presentation
Abstract Poster Presentation at The 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR:

"Detection of Epstein-Barr Virus Specific Functional T Cells By Flow Cytometry"

The ability to evaluate EBV specific T cell responses post-transplant is currently an unmet need for managing patients at risk of developing post-transplant lymphoproliferative disorder (PTLD). Functional impairment or lack of a T cell response to EBV has been predicted to drive the development of PTLD. Research indicates...

Click here to view the entire poster presentation.

Flebbe-Rehwaldt, L. Detection of Epstein-Barr Virus Specific Functional T Cells by Flow Cytometry. In: The 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR; April 23-26; Salt Lake City, UT; Abstract Number 479.

Results Reporting

RESULTS FOR:

EBV inSIGHT™ T Cell Immunity

  • Polyfunctional Index for EBV Antigens: CD4 EBV Cell Lysate, CD8 BZLF1 (lytic), CD8 EBNA 3A/3C (latent)
  • IFN-gamma Response for: CD4 EBV Cell Lysate, CD8 BZLF1 (lytic), CD8 EBNA 3A/3C (latent)
  • Control
  • Cell Viability

33217 - EBV inSIGHT™ T Cell Immunity

EBV inSIGHT™ T Cell Immunity Sample Report

Results For:

CMV inSIGHT™ T Cell Immunity

  • CMV Antigen
  • CD4
  • CD8
  • Control
  • Cell Viability
     

30360 - CMV inSIGHT™ T Cell Immunity Panel

WHITE PAPER

Evaluating Cytomegalovirus Cell Mediated Immunity Diagnostic Assays

Explore by Category

T Cell Immunity Testing - Flow Cytometry

How It Works

inSIGHT™ utilizes intracellular cytokine staining analyzed by flow cytometry to measure the strength of T cell responses to viral specific antigens or proteins. It evaluates and reports the activity of CD4 and CD8 T Cell responses separately.

 

Chat With An Expert

Back to top